14-Base pair polymorphism of human leukocyte antigen-G as genetic determinant in heart transplantation and cyclosporine therapy monitoring

Human Immunology

Volumn 70, Issue 10, 2009, Pages 830-835

  Torres, M I ^a   Luque, J ^b   Lorite, P ^a   Isla Tejera, B ^b   Palomeque, T ^a   Aumente, M D ^b   Arizon, J ^b   Pena J ^b  

^a UNIVERSITY OF JAÉN   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Cyclosporine treatment; Heart transplantation; HLA G polymorphism

Indexed keywords

CYCLOSPORIN; DEFLAZACORT; EVEROLIMUS; HLA G ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADOLESCENT; ADULT; ALTERNATIVE RNA SPLICING; ANTIBODY DETECTION; ARTICLE; BASE PAIRING; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART TRANSPLANTATION; HUMAN; IMMUNOGENETICS; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; RNA STABILITY;

ADOLESCENT; ADULT; ALLELES; ALTERNATIVE SPLICING; BASE PAIRING; CYCLOSPORINE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 70349309324     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.07.012     Document Type: Article

References (41)

1. Fehr T., and Sykes M. Tolerance induction in clinical transplantation. Transplant Immunol 13 (2004) 117-130
2. Awad M.R., Webber S., Boyle G., Sturchioĉ C., Ahmed M., Martell J., et al. The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. J Heart Lung Transplant 20 (2001) 625-630
3. Di Filippo S., Zeevi A., McDade K.K., Bastien O., and Webber S.A. Impact of TGF-beta1 gene polymorphisms on acute and chronic rejection in pediatric heart transplant allografts. Transplantation 81 (2006) 934-939
4. Simeoni E., Vassalli G., Seydoux C., Ramsay D., Noll G., Von Segesser L.K., et al. CCR5, RANTES and CX3CR1 polymorphisms: Possible genetic links with acute heart rejection. Transplantation 80 (2005) 1309-1315
5. Kovats S., Main E.K., Librach C., Stubblebine M., Fisher S.J., and DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science 248 (1990) 220-223
6. Houlihan J., Biro P., Harper H., Jenkinson H., and Holmes C. The human amnion is a site of MHC class Ib expression: Evidence for the expression of HLA-E and HLA-G. J Immunol 154 (1995) 5665-5674
7. Crisa L., McMaster M.T., Ishii J.K., Fisher S.J., and Salomon D.R. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med 186 (1997) 289-298
8. Blaschitz A., Lenfant F., Mallet V., Hartmann M., Bensussan A., Geraghty D.E., et al. Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Eur J Immunol 27 (1997) 3380-3388
9. Ishitani A., and Geraghty D. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II Antigens. Proc Natl Acad Sci U S A 89 (1992) 3947-3951
10. Hviid T.V.F. HLA-G in human reproduction: Aspects of genetics, function and pregnancy complications. Hum Reprod Update 12 (2005) 229-232
11. Lajoie J., Boivin A.A., Jeanneau A., Faucher M.C., and Roger M. Identification of six new HLA-G alleles with non-coding DNA base changes. Tissue Antigens 73 (2009) 379-380
12. Harrison G.A., Humphrey K.E., Jakobsen I.B., and Cooper D.W. A 14 bp deletion polymorphism in the HLA-G gene. Hum Mol Genet 2 (1993) 2200
13. Rousseau P., Le Discorde M., Mouillot G., Marcou C., Carosella E.D., and Moreau P. The 14 bp deletion-insertion polymorphism in the 3′ UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol 64 (2003) 1005-1010
14. Hviid T.V., Hylenius S., Rorbye C., and Nielsen L.G. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics 55 (2003) 63-79
15. Hviid T.V., Rizzo R., Christiansen O.B., Melchiorri L., Lindhard A., and Baricordi O.R. HLA-G and IL-10 in plasma in relation to HLA-G genotype and polymorphisms. Immunogenetics 56 (2004) 135-141
16. Yan W.H., Lin A., Chen X.J., Dai M.Z., Gan L.H., Zhou M.Y., et al. Association of the maternal 14-bp insertion polymorphism in the HLA-G gene in women with recurrent spontaneous abortions. Tissue Antigens 68 (2006) 521-523
17. Hviid T.V., and Christiansen O.B. Linkage disequilibrium between human leukocyte antigen (HLA) class II and HLA-G-possible implications for human reproduction and autoimmune disease. Hum Immunol 66 (2005) 688-699
18. Ristich V., Liang S., Zhang W., Wu J., and Horuzsko A. Tolerization of dendritic cells by HLA-G. Eur J Immunol 35 (2005) 1133-1142
19. Fournel S., Guerre-Girr M., Huc X., Lenfant F., Alam A., Toubert A., et al. Cutting edge: Soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8- cells by interacting with CD8. J Immunol 164 (2000) 6100
20. Le Gal F.-A., Riteau B., Sedlik C., Khalil-Daher I., Menier C., Dausset J., et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 11 (1999) 1351-1356
21. Marchal-Bras-Goncalves R., Rouas-Freiss N., Connan F., Choppin J., Dausset J., Carosella E.D., et al. A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity. Transplant Proc 33 (2001) 2355-2359
22. Kapasi K., Albert S.E., Yie S., Zavazava N., and Librach C.L. HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. Immunology 101 (2000) 191-200
23. Lila N., Rouas-Freiss N., Dausset J., Carpentier A., and Carosella E.D. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: A CD4+ T cell regulatory mechanism. Proc Natl Acad Sci USA 98 (2001) 12150-12155
24. Luque J., Torres M.I., Aumente M.D., Marín J., García-Jurado G., González R., et al. Soluble HLA-G in heart transplantation: Their relationship to rejection episodes and immunosuppressive therapy. Hum Immunol 67 (2006) 257-263
25. Luque J., Torres M.I., Aumente M.D., Lozano J.M., García-Jurado G., González R., et al. sHLA-G levels in the monitoring of immunosuppressive therapy and rejection following heart transplantation. Transpl Immunol 17 (2006) 70-73
26. Lila N., Amrein C., Guillemain R., Chevalier P., Fabiani J.N., and Carpentier A. Soluble human leukocyte antigen-G: A new strategy for monitoring acute and chronic rejection after heart transplantation. J Heart Lung Transplant 26 (2007) 412-422
27. Crispim J.C., Duarte R.A., Soares C.P., Costa R., Silva J.S., Mendes-Júnior C.T., et al. Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection. Transplant Immunol 18 (2008) 361-367
28. Sheshgiri R., Rouas-Freis N., Rao V., Butany J., Ramzy D., Krawice-Radane I., et al. Myocardial HLA-G reliable indicates a low risk of acute cellular rejection in heart transplant recipient. J Heart Lung Transplant 27 (2008) 522-527
29. Piancatelli D., Maccarone D., Liberatore G., Parzanese I., Clemente K., Azzarone R., et al. HLA-G 14-bp insertion/deletion polymorphism in kidney transplant patients with metabolic complications. Transplant Proc 41 (2009) 1187-1188
30. Mueller X.M. Drugs immunosuppression theraphy for adult heart transplantation. Part 1. Immune response to allograft and mechanism of action of immunosupressants. Ann Thorac Surg 77 (2004) 354-362
31. Masuda S., and Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 112 (2006) 184-198
32. Diciolla F., Scolletta S., Berti L., Maccherini M., Federici D., Bernazzali S., et al. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients. Transplant Proc 37 (2006) 1355-1359
33. Weber L.T., Armstrong V.W., Shipkova M., Feneberg R., Wiesel M., Mehls O., et al. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. Ther Drug Monit 26 (2004) 415-424
34. Tripathi P., Abbas A., Naik S., and Agrawal S. Role of 14-bp deletion in the HLA-G gene in the maintenance of pregnancy. Tissue Antigens 64 (2004) 706-710
35. Veit T.D., Vianna P., Scheibel I., Brenol C., Brenol J.C., Xavier R.M., et al. Association of the HLA-G 14-bp insertion/deletion polymorphism with juvenile idiopathic arthritis and rheumatoid arthritis. Tissue Antigens 71 (2008) 440-446
36. Crispim J.C., Mendes-Junior C.T., Wastowski I.J., Costa R., Castelli E.C., Saber L.T., et al. Frequency of insertion/deletion polymorphism in exon 8 of HLA-G and kidney allograft outcome. Tissue Antigens 71 (2008) 35-41
37. Rebmann V., Van der Ven K., Passler M., Pfeiffer K., Krebs D., and Grosse-Wilde H. Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens 57 (2001) 15-21
38. Hviid T.V., Hylenius S., Hoegh A.M., Kruse C., and Christiansen O.B. HLA-G polymorphisms in couples with recurrent spontaneous abortions. Tissue Antigens 60 (2002) 122-132
39. La Nasa G., Littera R., Locatelli F., Lai S., Alba F., Caocci G., et al. The human leucocyte antigen-G 14-basepair polymorphism correlates with graft-versus-host disease in unrelated bone marrow transplantation for thalassaemia. Br J Haematol 139 (2007) 284-288
40. Le Rond S., Azema C., Krawice-Radanne I., Durrbach A., Guettier C., Carosella E.D., and Rouas-Freiss N. Evidence to support the role of HLA-G in allograft acceptance though induction of immunosuppressive/regulatory T cells. J Immunol 176 (2006) 3266-3276
41. Einecke G., Mai I., Diekmann F., Fritsche L., Neumayer H.H., and Budde K. Cyclosporine absorption profiling and therapeutic drug monitoring using C(2) blood levels in stable renal allograft recipients. Transplant Proc 34 (2002) 1738-1739